FOLH1 and posterior cortical atrophy: Targeted therapies against newly identified tissue-specific proteins, such as the prostate-specific membrane antigen (PSMA), a transmembrane glycoprotein, whose levels gradually increase from normal epithelium to PCa, have been also proposed as promising theranostic agents that could improve both diagnostic accuracy and therapeutic efficacy [117].